Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist

  • Trends Pharmacol Sci. 1997 Jun;18(6):186-8. doi: 10.1016/s0165-6147(97)01066-3.
L J Bristow  1 ,  M S Kramer ,  J Kulagowski ,  S Patel ,  C I Ragan ,  G R Seabrook
Affiliations
  • 1. Department of Pharmacology, Merck, Sharp and Dohme, Neuroscience Research Centre, Terlings Park, Harlow, UK.
PMID: 9226994 DOI: 10.1016/s0165-6147(97)01066-3
Abstract

The discovery of a novel high-affinity and selective dopamine D4 receptor antagonist, L-745,870, and the results of clinical trials with this compound are reviewed. Despite several lines of evidence which suggest that a selective D4 receptor antagonist may be an effective antipsychotic agent with a lower propensity to induce extrapyramidal side-effects, L-745,870 was ineffective as an antipsychotic in humans.

Products